Betta Pharmaceuticals released its 2026 interim report, with net profit attributable to the parent company of 302 million yuan, up 115.97% from the same period last year. Total operating revenue was 1.976 billion yuan, an increase of 245 million yuan from the same period last year, up 14.12% year-on-year, marking five consecutive years of growth. Net cash inflow from operating activities was 412 million yuan, a decrease of 32.6386 million yuan from the same period last year, down 7.33% year-on-year. The company's latest asset-liability ratio was 35.56%, down 2.72 percentage points from the same period last year; the latest gross margin was 76.43%, down 4.75 percentage points from the same period last year; the latest return on equity was 4.56%, up 2.06 percentage points from the same period last year. Diluted earnings per share were 0.72 yuan, an increase of 0.39 yuan from the same period last year, up 118.18% year-on-year.
Betta Pharmaceuticals Co LtdNet profit up 115.97% year-on-year, revenue up 14.12%, and EPS up 118.18%.
